US Bancorp DE Makes New $39,000 Investment in Gossamer Bio, Inc. (NASDAQ:GOSS)

US Bancorp DE acquired a new stake in Gossamer Bio, Inc. (NASDAQ:GOSS) during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund acquired 39,655 shares of the company’s stock, valued at approximately $39,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. NEA Management Company LLC lifted its holdings in shares of Gossamer Bio by 14.2% in the 2nd quarter. NEA Management Company LLC now owns 18,093,034 shares of the company’s stock valued at $16,300,000 after purchasing an additional 2,255,025 shares during the last quarter. Monaco Asset Management SAM increased its holdings in shares of Gossamer Bio by 390.3% in the 2nd quarter. Monaco Asset Management SAM now owns 2,726,104 shares of the company’s stock valued at $2,456,000 after acquiring an additional 2,170,104 shares during the period. Marshall Wace LLP raised its position in Gossamer Bio by 170.8% in the 2nd quarter. Marshall Wace LLP now owns 3,335,511 shares of the company’s stock valued at $3,002,000 after purchasing an additional 2,103,766 shares during the last quarter. Renaissance Technologies LLC boosted its stake in Gossamer Bio by 204.7% during the 2nd quarter. Renaissance Technologies LLC now owns 2,046,600 shares of the company’s stock worth $1,844,000 after purchasing an additional 1,375,000 shares during the period. Finally, Acadian Asset Management LLC grew its position in Gossamer Bio by 51.6% during the 1st quarter. Acadian Asset Management LLC now owns 2,736,385 shares of the company’s stock worth $3,227,000 after purchasing an additional 931,248 shares during the last quarter. 81.23% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Wedbush reiterated an “outperform” rating and set a $4.00 target price on shares of Gossamer Bio in a research note on Tuesday, August 13th. HC Wainwright reissued a “buy” rating and issued a $10.00 price objective on shares of Gossamer Bio in a research note on Monday, November 11th. Five analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $9.20.

Gossamer Bio Stock Down 2.7 %

Gossamer Bio stock opened at $0.72 on Tuesday. The stock’s 50 day moving average price is $0.93 and its 200 day moving average price is $0.87. The company has a market cap of $163.17 million, a PE ratio of -2.25 and a beta of 1.96. The company has a debt-to-equity ratio of 3.64, a current ratio of 6.74 and a quick ratio of 6.74. Gossamer Bio, Inc. has a 1-year low of $0.50 and a 1-year high of $1.60.

Gossamer Bio (NASDAQ:GOSS) last announced its quarterly earnings results on Thursday, November 7th. The company reported ($0.14) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.18) by $0.04. The company had revenue of $9.48 million during the quarter, compared to analysts’ expectations of $4.52 million. On average, sell-side analysts predict that Gossamer Bio, Inc. will post -0.28 EPS for the current fiscal year.

Gossamer Bio Company Profile

Gossamer Bio, Inc, a clinical-stage biopharmaceutical company, focuses on developing and commercializing seralutinib for the treatment of pulmonary arterial hypertension (PAH) in the United States. The company is developing GB002, an inhaled, small molecule, platelet-derived growth factor receptor, or PDGFR, colony-stimulatin factor 1 receptor and c-KIT inhibitor, which is in Phase 3 clinical trial for the treatment of PAH.